<DOC>
	<DOCNO>NCT00871858</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use anastrozole may fight breast cancer lower amount estrogen body make . Fulvestrant may fight breast cancer block use estrogen tumor cell . It yet know whether anastrozole effective fulvestrant surgery radiation therapy treat patient breast cancer . PURPOSE : This randomized phase II trial study anastrozole see well work compare fulvestrant treat postmenopausal patient breast cancer .</brief_summary>
	<brief_title>Anastrozole Fulvestrant Treating Postmenopausal Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate clinical tumor response 6 month patient hormone-sensitive nonmetastatic breast cancer treat neoadjuvant anastrozole v fulvestrant . Secondary - Evaluate tumor regression mammography ultrasound patient . - Evaluate rate breast conservation 6 month treatment patient . - Evaluate tolerability regimen . - Estimate progression-free survival 5 year patient . - Identify molecular signature predictive response patient . - Identify gene implicate response patient . - Identify change mRNA splice gene involve breast tumorigenesis . OUTLINE : This multicenter study . All patient undergo biopsy baseline . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral anastrozole daily 6 month . - Arm II : Patients receive fulvestrant intramuscularly day 1 , 14 , 28 month 2-6 month . Within 8 day completion hormone therapy , patient undergo surgical resection residual lesion follow radiotherapy . Patients receive oral anastrozole daily 5 year . Tissue sample biopsy surgery analyze assess molecular signature sensitivity treatment , compare gene expression variation response .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer , meet 1 follow criterion : SBR grade III disease ( patient &lt; 65 year age ) SBR grade IIII disease ( patient &gt; 65 year age ) T2 ( 25 cm ) , T3 , T4B , N01 disease No metastatic disease Breast lesion amenable breastconserving resection No inflammatory breast cancer No prior breast cancer Hormone receptor status : Estrogen receptor and/or progesterone receptorpositive PATIENT CHARACTERISTICS : Postmenopausal No cancer within past 5 year except adequately treat skin carcinoma carcinoma situ cervix No contraindication antihormonal treatment No psychological , familial , social , geographical reason would preclude follow PRIOR CONCURRENT THERAPY : At least 8 day since prior hormone replacement therapy No concurrent antivitamin K treatment</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
</DOC>